As­traZeneca scraps oral GLP-1 af­ter PhI ‘does not meet that am­bi­tion’ of trump­ing the com­pe­ti­tion

As the com­pe­ti­tion heats up in the GLP-1 space, some are bound to get out and find oth­er ways of de­liv­er­ing di­a­betes and obe­si­ty drugs. One such com­pa­ny is As­traZeneca, which cit­ed the com­pe­ti­tion in end­ing an ear­ly-stage study of its oral GLP-1.

The UK Big Phar­ma is do­ing away with AZD0186 af­ter tak­ing a look at Phase I da­ta from a sin­gle as­cend­ing dose study of the oral drug in healthy vol­un­teers, per an up­date to the US fed­er­al tri­als data­base in re­cent days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER